StockData

Kewaunee Scientific vs Mesa Laboratories

KEQU and MLAB side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KEQU and MLAB compare

Mesa Laboratories is the larger company, worth 7.4 times as much as Kewaunee Scientific ($750M against $101M).

On earnings, Kewaunee Scientific is cheaper: it trades at 12.7× trailing earnings, against 158× for Mesa Laboratories.

Kewaunee Scientific grew revenue faster over the last twelve months (5.3% versus 3.0% for Mesa Laboratories).

Kewaunee Scientific keeps more of each dollar of sales as profit, with a net margin of 3.0% compared with 1.9% at Mesa Laboratories.

Mesa Laboratories pays a dividend yielding 0.48%; Kewaunee Scientific does not pay one.

Kewaunee Scientific scores higher on the StockData Score (14 against 11 for Mesa Laboratories), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKEQUMLAB
Size and price
Market cap$101M$750M
Share price$35.05$134.09
Change, 1 year−12.5%76.8%
Change, 5 years170%−57.1%
Beta (5Y)0.791.00
Employees–717
StockData Score
Total score14 (better)11
Valuation score5 (better)0
Growth score12 (better)
Performance score44
Health score4 (better)1
Dividend score04 (better)
Valuation
P/E12.7× (better)158×
P/S0.4× (better)3.0×
P/B1.4× (better)4.0×
EV/EBITDA5.3× (better)32.0×
P/FCF9.3× (better)14.2×
PEG0.09 (better)1.71
FCF yield10.7% (better)7.0%
Fair value$76.96$71.16
Margin of safety54.5% (better)−88.4%
Growth
Revenue growth (TTM)5.3% (better)3.0%
Revenue growth, 5Y average13.8% (better)13.2%
Net income growth (TTM)−33.1%–
EPS growth (TTM)−33.2%–
EPS growth, 5Y average–13.6%
Profitability
Gross margin28.6%64.2% (better)
Operating margin5.4%9.0% (better)
Net margin3.0% (better)1.9%
FCF margin3.9%21.2% (better)
Return on equity11.6% (better)2.7%
Return on invested capital13.1% (better)7.5%
Financial health
Debt / equity0.25–
Net debt / EBITDA0.50–
Interest coverage4.4× (better)2.1×
Current ratio2.20 (better)1.79
Altman Z-score3.42 (better)2.24
Piotroski F-score48 (better)
Dividends and buybacks
Dividend yield–0.48%
Payout ratio–73.6%
Years of dividend growth–0
Dividend growth, 5Y average–0.00%
Shareholder yield0.00%0.48% (better)
Ownership
Held by institutions41.4%89.9%
Held by insiders16.1%3.6%
Insider net buying, 12 months−$293K−$216K (better)
Short interest, % of float1.6%7.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.